At a glance
ClinicalIndex Comparison RecordN/ACompleted· 79 enrolled
Drug / intervention
Light Adjustable lens (LAL) and Light Delivery Device (LDD)device
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Single Center Exploratory Study To Evaluate The Use Of The RxSight Light Adjustable Lens (LAL) And The Light Delivery Device (LDD) To Improve Visual Outcomes
In Brief
A clinical study evaluating Light Adjustable lens (LAL) and Light Delivery Device (LDD) for Aphakia and Cataract. Completed, enrolled 79 participants across 1 site.
Detailed Summary
The objective of this study is to evaluate, for the visual correction of aphakia, whether the RxSight Light Adjustable Lens (LAL) and Light Delivery Device (LDD) can be used to improve visual outcomes after performing adjustments of the LAL with the LDD. This is an exploratory study. No primary effectiveness endpoints will be identified.
Study Details
Timeline
N/ACompletedFinished
202120222023202420252026
Enrollment StartMay 2020
First PostedAug 2020
Primary CompletionOct 2022
TodayJul 2026
First PostedAug 27, 2020
Enrollment StartMay 22, 2020
Primary CompletionOct 1, 2022
TodayJul 2, 2026
Enrollment to primary: 2.4 yearsPosted 5.8 years ago
Interventions
Light Adjustable lens (LAL) and Light Delivery Device (LDD)device
Eligible eyes will receive Light adjustable lens with Light delivery Device treatments